Marksans Pharma Q4 Results
- BSE: 524404
- NSE: MARKSANS
- ISIN: INE750C01026
- Sector: Biotechnology & Drugs
BSE
274.00
4.95 (1.84%)
4.95 (1.84%)Volume62.39 K
Updated: Fri 7 Aug, 2026 | 15:29:49
NSE
273.854.95 (1.84%)
4.95 (1.84%)Volume1.01 M
Updated: Fri 7 Aug, 2026 | 15:50:58
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹856.11 Cr.(20.84%)
- Operating Profit₹171.13 Cr.(66.13%)
- Profit After Tax₹148.13 Cr.(63.60%)
- Operating Margin19.99%(37.48%)
Note: Comparison is on YoY basis
Quarterly - Marksans Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 684.98 | 618.01 | 10.84% | 471.43 | 13.14% |
| Depreciation/ Amortization | 24.29 | 24.33 | -0.16% | 21.06 | 6.78% |
| Operating Income | 171.13 | 136.42 | 25.45% | 88.58 | 66.13% |
| Net Income | 148.13 | 113.20 | 30.85% | 78.29 | 63.60% |
| Other Operating Expenses Total | 163.28 | 165.47 | -1.32% | 100.80 | 1.88% |
| Net Income Before Taxes | 200.00 | 150.62 | 32.78% | 100.27 | 72.27% |
| Total Revenue | 856.11 | 754.43 | 13.48% | 560.01 | 20.84% |
| Selling/ General/ Admin Expenses Total | 106.76 | 111.99 | -4.67% | 79.75 | 9.81% |
| Diluted Normalized EPS | 3.27 | 2.50 | 30.73% | 1.73 | 63.55% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.